Japan's Takeda Chemical Industries says that the European Committee forProprietary Medicinal Products has adopted a positive opinion, recommending the marketing authorization of its Ixense (apomorphine HCl sublingual tablets) for the treatment of erectile dysfunction. The company says that its subsidiary, Takeda Europe, will work with the European authorities to receive final clearance of the product.
Similarly, Abbott Laboratories has announced CPMP backing for its Uprima (apomorphine HCl), for which it holds non-exclusive marketing rights outside the USA and Canada. Abbott has licensed the product from TAP Pharmaceuticals (its joint venture with Takeda), which itself acquired rights to the sublingual tablets for male ED from Pentech Pharmaceuticals.
Erection achieved within 20 minutes
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze